110 related articles for article (PubMed ID: 21971005)
1. Multimodal drugs and their future for Alzheimer's and Parkinson's disease.
Van der Schyf CJ; Geldenhuys WJ
Int Rev Neurobiol; 2011; 100():107-25. PubMed ID: 21971005
[TBL] [Abstract][Full Text] [Related]
2. The emergence of designed multiple ligands for neurodegenerative disorders.
Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
[TBL] [Abstract][Full Text] [Related]
3. Can we prevent Parkinson's and Alzheimer's disease?
Kedar NP
J Postgrad Med; 2003; 49(3):236-45. PubMed ID: 14597787
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase-B inhibition in Alzheimer's disease.
Riederer P; Danielczyk W; Grünblatt E
Neurotoxicology; 2004 Jan; 25(1-2):271-7. PubMed ID: 14697902
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
6. Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects.
Mathé G
Biomed Pharmacother; 1995; 49(4):161-7. PubMed ID: 7669935
[TBL] [Abstract][Full Text] [Related]
7. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
11. Future directions in the treatment of Parkinson's disease.
Schapira AH
Mov Disord; 2007 Sep; 22 Suppl 17():S385-91. PubMed ID: 18175401
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
13. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
Koutsilieri E; Riederer P
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
[TBL] [Abstract][Full Text] [Related]
14. Lewy body diseases with dementia: pathophysiology and treatment.
Cummings JL
Brain Cogn; 1995 Aug; 28(3):266-80. PubMed ID: 8546854
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
Stocchi F
Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
[TBL] [Abstract][Full Text] [Related]
16. [New therapeutic options in Alzheimer's disease].
García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline in Parkinson's disease.
Chahine LM; Stern MB
Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
